Cipla recalls over 400 cartons of cancer drug in US: FDA
Thursday, March 12, 2026
2 min read
Canonical SourceIndia
Summary Only
What Changed
Cipla is voluntarily recalling over 400 cartons of Nilotinib Capsules in the US due to a manufacturing defect, impacting product availability.
Sigvera Intelligence
Source Trust:Discovery
Company ActivityView all
Source Report
Cipla is recalling over 400 cartons of Nilotinib Capsules in the US due to a manufacturing defect.
Industry Context
Healthtech & Biotech
Where this signal fits in the broader landscape.
115 industry signalsRegulatory & Policy
Source Verification
Verified from official source
Publisher—
Publication DateMar 12, 2026
Source ClassVerified Canonical
Signal Timeline
First ReportedMar 12, 2026
IndexedMar 12, 2026
PublishedMar 12, 2026
https://pharma.economictimes.indiatimes.com/news/pharma-industry/cipla-recalls-over-400-cartons-of-cancer-drug-in-us-fda/129302185
Read Full SourceGet cross-language signal intelligence
Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
My Notes
Sign in to save notes on signals.
Sign In